期刊文献+

培美曲塞联合铂类药物一线用药治疗晚期非小细胞肺癌(NSCLC)的近期及远期疗效 被引量:7

下载PDF
导出
摘要 目的探讨培美曲塞联合铂类药物一线用药治疗晚期非小细胞肺癌(NSCLC)的近期及远期疗效。方法本研究选取了62例晚期非小细胞肺癌患者作为研究对象,将患者随机分为对照组和观察组,每组31例,对照组患者采用培美曲塞联合卡铂治疗,观察组患者采用培美曲塞联合顺铂治疗,对比2组患者的临床疗效。结果对照组患者的治疗总有效率为38.7%,观察组患者的治疗总有效率为32.3%,2组的近期治疗总有效率差异无统计学意义。对照组患者的中位生存期为(11.1±2.2)个月,1年生存率为48.4%;观察组患者的中位生存期为(10.9±2.0)个月,1年生存率为45.2%,2组患者的中位生存期及1年生存率相比差异无统计学意义。2组患者的恶心呕吐、贫血、白细胞减少、中性粒细胞减少、肝功能异常、皮疹不良反应发生率比较差异无统计学意义。与对照组相比,观察组患者的血小板减少发生率显著降低,差异具有统计学意义(P<0.05)。结论培美曲塞联合铂类药物一线用药治疗晚期非小细胞肺癌的近期及远期疗效较好,患者的不良反应发生率较低,且培美曲塞联合顺铂治疗患者的血小板减少发生率明显降低。 Objective To study the pemetrexed combined platinum drugs first-line drug treatment of advanced non-small cell lung cancer (NSCLC), recent and forward curative effect. Methods This study selectedl 90 cases of advanced non-small cell lung cancer patients as the research object, the patients were randomly divided into control group and observation group, 31 cases in each group, control group were treated by pemetrexed plus carboplatin treatment, the observation group were treated by pemetrexed combined cisplatin treatment, compared the clinical efficacy of two groups of patients. Results The treatment of patients with control group the total effective rate was 38.7%, the observation group of patients with treatment the total effective rate was 32.3%, two groups of the recent treatment of total effective rate of no statistical difference. Control group patients' median survival was (11.1±2.2) months, 1 year survival rate was 48.4%, the observation group of patients with a median surial was (10.9±2.0) months, 1 year survival rate was 45.2%, two groups of patients with a median survival and 1 year survival rate compared with no statistical difference. Two groups of patients with nausea and vomiting, anemia, leukopenia and neutropenia, abnormal liver function, skin rashes, incidence of adverse reaction no statistical difference. Compared with control group, the observation group of patients with significantly reduce the incidence of thrombocytopenia, and difference statistically difference (P〈 0.05). Conclusion Joint platinum drug pemetrexed first-line drug treatment of advanced non-small cell lung cancer in the near future and the forward curative effect is better, in patients with a low incidence of adverse reaction, and pemetrexed combined cisplatin in the treatment of patients with significantly lower incidence of thrombocytopenia,
出处 《当代医学》 2016年第11期125-127,共3页 Contemporary Medicine
关键词 培美曲塞 铂类药物 一线用药 晚期 非小细胞肺癌 Pemetrexed The platinum drugs A gleam of drug use The late Non-small cell lung cancer
  • 相关文献

参考文献8

二级参考文献61

  • 1Schiller JH,Harrington D,Belani CP,et al.Eastern Cooperative Oncology Group.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346 (2):92-98.
  • 2Therasse P,Arbuck SG,Eiscilhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumor[J].J Natl Cancer Inst,2000,92 (3):205-216.
  • 3Manegold C,Gatzemeier U,Von Pawel J,et al.Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514,pometrexed disodium,ALIMTA) and cisplatin:a multicenter phase Ⅱ trial[J].Ann Oncol,2000,11(4):435-440.
  • 4Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly[ J]. Eur J Cancer, 1997,33 (14) :2313-2314.
  • 5Han K, Cao W, Che J, et al. First line chemotherapy with weekly docetaxel and cisplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study[J]. J Thorac Oncol, 2009, 4(4) :512-517.
  • 6Tibaldi C, Vasile E, Antonuzzo A, et al. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients : a multicenter phase II study [ J ]. Br J Cancer, 2008,98 ( 3 ) :558-563.
  • 7Giorgio CG, Pappalardo A, Russo A, et al. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC) [ J ]. Lung Cancer, 2006, 51 ( 3 ) :357-362.
  • 8Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) : a risk-benefit analysis[J]. J Thorac Oncol, 2007, 2(5) :397-401.
  • 9Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004, 22(9) :1589-1597,.
  • 10Kulkarni PM, Chen R, Anand T, et al. Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis [ J ]. Crit Rev Oncol Hematol, 2008, 67 (1): 64-70.

共引文献119

同被引文献64

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部